enGene Therapeutics (ENGN) Depreciation & Amortization (CF) (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Depreciation & Amortization (CF) of $200000.0 for Q2 2026, up 100.0% year-over-year from $100000.0 in Q2 2025, and up 5.82% quarter-over-quarter from $189000.0 in Q1 2026.
enGene Therapeutics (ENGN) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $200000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 100.0% year-over-year to $200000.0; the TTM figure through Apr 2026 stood at $689000.0 (up 71.39% YoY), while the FY2025 annual figure was $500000.0, up 66.67% from the prior year.
- Depreciation & Amortization (CF) rose to $200000.0 in Q2 2026 per ENGN's latest filing, from $189000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $200000.0 in Q4 2025 and bottomed at $37000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $105071.4 across 4 years, with a median of $100000.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 170.27% — and 2025, when it changed 0.0%.
- enGene Therapeutics' Depreciation & Amortization (CF) stood at $74000.0 in 2023, then jumped by 35.14% to $100000.0 in 2024, then surged by 100.0% to $200000.0 in 2025, then changed by 0.0% to $200000.0 in 2026.
- Business Quant data shows ENGN's Depreciation & Amortization (CF) at $200000.0 in Q2 2026, $189000.0 in Q1 2026, and $200000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 200,000.00 |
| Apr 30, 2026 | 200,000.00 |
| Jan 31, 2026 | 189,000.00 |
| Jan 31, 2026 | 189,000.00 |
| Oct 31, 2025 | 200,000.00 |
| Oct 31, 2025 | 200,000.00 |
| Jul 31, 2025 | 100,000.00 |
| Jul 31, 2025 | 100,000.00 |
| Apr 30, 2025 | 100,000.00 |
| Apr 30, 2025 | 100,000.00 |
| Jan 31, 2025 | 102,000.00 |
| Jan 31, 2025 | 102,000.00 |
| Oct 31, 2024 | 100,000.00 |
| Oct 31, 2024 | 100,000.00 |
| Jul 31, 2024 | 100,000.00 |
| Jul 31, 2024 | 100,000.00 |
| Apr 30, 2024 | 100,000.00 |
| Apr 30, 2024 | 100,000.00 |
| Jan 31, 2024 | 80,000.00 |
| Jan 31, 2024 | 80,000.00 |